MedTrace Logo

Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma

NCT01472757 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 374

Last updated 2020-04-21

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the clinical efficacy of three doses of VR506 delivered via a new dry powder inhaler for the treatment of asthma.

Conditions

Interventions

DRUG

VR506

VR506 inhalation powder delivered via a new dry powder inhaler

DRUG

Placebo

Placebo delivered via a new dry powder inhaler

Sponsors & Collaborators

  • Vectura Limited

    lead INDUSTRY

Principal Investigators

  • Ronald Dahl, Dr. · Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States
  • Philippines
  • Poland
  • Romania
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01472757 on ClinicalTrials.gov